Neuron23 was founded in 2018 and came out of stealth mode in 2020. We have offices and labs in South San Francisco and have raised a total of $113.5 million—$33.5 million in Series A funding from Kleiner Perkins and Westlake Village BioPartners and $80 million in Series B funding led by Redmile Group.

Our vision is to build a high science, execution-driven biotechnology company focused on developing medicines for devasting neurological and inflammatory disorders.

We welcome partner queries from investors, scientists, academics, and other interested parties who can help us to expedite the advancement of our pipeline and bring our innovative therapies to patients rapidly.

To find out more, please get in touch.